Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 6/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812129 | 0.89 | P2RX7 (0.44) | CACNA1GCACNA1HCACNA1IKMT2AP2RX7 | |
| SCHEMBL2814282 | 0.88 | KMT2A (0.42) | CACNA1GCACNA1HCACNA1IKMT2AMEN1 | |
| SCHEMBL2811925 | 0.88 | CACNA1G (0.42) | CACNA1GCACNA1HCACNA1IP2RX7ALDH1A1 | |
| SCHEMBL2815942 | 0.88 | MC4R (0.43) | CACNA1GCACNA1HCACNA1IKDM4EP2RX7 | |
| SCHEMBL538332 | 0.85 | CACNA1G (0.39) | CACNA1GCACNA1HCACNA1IKMT2ASMN1; SMN2 | |
| SCHEMBL2812033 | 0.85 | P2RX7 (0.42) | CACNA1GCACNA1HCACNA1IKMT2AMEN1 | |
| SCHEMBL538002 | 0.84 | KDM1A (0.41) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL13131765 | 0.84 | KMT2A (0.40) | CACNA1GCACNA1HCACNA1IKMT2AEPHX2 | |
| SCHEMBL2812141 | 0.84 | ALDH1A1 (0.43) | CACNA1GCACNA1HCACNA1IKDM4EKMT2A | |
| SCHEMBL537587 | 0.83 | ALDH1A1 (0.48) | KDM4EKMT2AMEN1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414359-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | CACNA1G 4588/4885CACNA1H 4714/4885CACNA1I 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.